NASDAQ · AGLE
Healthcare · Biotechnology
$12.01
Up+$0.75 (+6.66%)
Updated Aug 15, 2026, 1:29 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
AGLE does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning AGLE.
AGLE research
Company profile and research snapshot.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 16, 2023 | Wells Fargo | Equal-Weight | — |
| Jul 25, 2023 | Stifel | Buy | — |
| Apr 12, 2023 | LifeSci Capital | Market Perform | — |
| Apr 12, 2023 | JonesTrading | Hold | — |
| Mar 3, 2023 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Zacks Investment Research · Jun 23, 2023
Aeglea's (AGLE) shares surge as it acquires Spyre Therapeutics, a private company that focuses on developing antibody therapeutics for inflammatory bowel disease.
PennyStocks · Jun 23, 2023
Use these tips to guard your penny stock investments against large market movement The post How to Guard Your Penny Stocks Against Market Movement appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research · May 11, 2023
Aeglea (AGLE) delivered earnings and revenue surprises of -5.26% and 16.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 9, 2023
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 68.75% and 5.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AGLE.
No results
No recent SID articles mention AGLE.
